

THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014 AS AMENDED BY REGULATION 11 OF THE MARKET ABUSE (AMENDMENT) (EU EXIT) REGULATIONS 2019/310 UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA REGULATORY INFORMATION SERVICE, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.

4 January 2024

VALIRX PLC

("ValiRx" or the "Company")

Result of General Meeting

Issue of Equity and Total Voting Rights

Director and PDMR Shareholding

ValiRx plc (the "Company") (AIM: VAL), announces that, further to the Conditional Fundraise & Notice of General Meeting announcement dated 13 December 2023, at its General Meeting held earlier today, resolutions 1 and 3 were duly passed and resolution 2 was not passed. Details of the votes received in respect of the resolutions will be available shortly on the Company's website.

Director and PDMR Shareholdings

Following completion of the Fundraising, the shareholdings of the Directors and PDMRs who participated in the Fundraising are set out in the table below:

<i>Director/PDMR</i>	<i>Existing beneficial shareholding</i>	<i>Fundraising Shares subscribed for</i>	<i>Beneficial shareholding on completion of the Fundraising</i>	<i>Beneficial shareholding as a percentage of the Enlarged Share Capital</i>
Suzanne Dilly	416,668	66,666	483,334	0.37%
Kevin Cox	372,333	150,000	522,333	0.39%
Gerry Desler	128,668	66,666	195,334	0.15%
Martin Lampshire	144,000	150,000	294,000	0.22%
Stella Panu	-	333,333	333,333	0.25%
Cathy Tralau-Stewart	-	66,666	66,666	0.05%

Issue of Equity

The Placing Shares, the Subscription Shares and the Retail Offer Shares have been allotted, conditional upon Admission, and application has been made to the London Stock Exchange for, in aggregate, 30,029,063 Placing Shares, Subscription Shares and Retail Offer Shares to be admitted to trading on AIM. Admission is expected to occur at 8.00 a.m. on 8 January 2024, with dealings in the Placing Shares, the Subscription Shares and the Retail Offer Shares commencing at the same time. The Placing Shares, the Subscription Shares and the Retail Offer Shares will rank *pari passu* with all other issued Shares.

The Fundraising remains conditional, *inter alia*, upon Admission and the Placing Agreement not being terminated in accordance with its terms.

Total Voting Rights

For the purpose of the Disclosure Guidance and Transparency Rules, following Admission the enlarged issued share capital of the Company will comprise 132,348,673 ordinary shares of 0.1 pence each. The Company does not hold any shares in the treasury. The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the Disclosure Guidance and Transparency Rules.

Capitalised terms used in this announcement have the meaning given to them in the Conditional Fundraise, Notice of General Meeting announcement dated 13 December 2023, unless otherwise defined in this announcement.

The Directors of the Company take responsibility for this announcement.

For more information, please contact:

ValiRx plc Dr Suzanne Dilly, CEO	Tel: +44 (0) 2476 796496 www.valirx.com Suzanne.Dilly@valirx.com
V Formation (Public Relations) Lucy Wharton - Senior PR Executive Sue Carr - Director	+44 (0) 115 787 0206 www.vformation.biz lucy@vformation.biz sue@vformation.biz
Cairn Financial Advisers LLP (Nominated Adviser) Liam Murray/Jo Turner/Ludovico Lazzaretti	Tel: +44 (0) 20 7213 0880
Cavendish Capital Markets Limited (Joint Broker) Dale Bellis/Michael Johnson (Sales) Callum Davidson/Giles Balleny (Corporate Finance)	Tel: +44 (0) 20 7397 8900
Turner Pope Investments (Joint Broker) James Pope / Andy Thacker	Tel: +44 (0) 20 3657 0050

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014		
1 Details of the person discharging managerial responsibilities/person closely associated		
a.	Name	a) Suzanne Dilly b) Kevin Cox c) Gerry Desler d) Martin Lampshire e) Stella Panu f) Cathy Tralau-Stewart
2 Reason for notification		
a.	Position/Status	a) Director b) Director c) Director d) Director e) Director f) PDMR
b.	Initial notification/ Amendment	Initial notification

3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor															
a.	Name	ValiRx PLC														
b.	LEI	213800VQKB9SJCQDET40														
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted															
a.	Description of the financial instrument, type of instrument Identification Code	Ordinary Shares ISIN: GB00BLH13C52														
b.	Nature of the transaction	Purchase of shares as part of the Fundraising														
c.	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>a) 6p</td> <td>a) 66,666</td> </tr> <tr> <td>b) 6p</td> <td>b) 150,000</td> </tr> <tr> <td>c) 6p</td> <td>c) 66,666</td> </tr> <tr> <td>d) 6p</td> <td>d) 150,000</td> </tr> <tr> <td>e) 6p</td> <td>e) 333,333</td> </tr> <tr> <td>f) 6p</td> <td>f) 66,666</td> </tr> </tbody> </table>	Price(s)	Volume(s)	a) 6p	a) 66,666	b) 6p	b) 150,000	c) 6p	c) 66,666	d) 6p	d) 150,000	e) 6p	e) 333,333	f) 6p	f) 66,666
Price(s)	Volume(s)															
a) 6p	a) 66,666															
b) 6p	b) 150,000															
c) 6p	c) 66,666															
d) 6p	d) 150,000															
e) 6p	e) 333,333															
f) 6p	f) 66,666															
d.	Aggregated information - Aggregated Volume - Price	N/A														
e.	Date of the transaction	a) 04/01/2024 b) 04/01/2024 c) 04/01/2024 d) 04/01/2024 e) 04/01/2024 f) 04/01/2024														
f.	Place of the transaction	Outside a trading venue														

Notes for Editors

About ValiRx

ValiRx is a life science company focused on early-stage cancer therapeutics and women's health, accelerating the translation of innovative science into impactful medicines to improve patient lives.

ValiRx provides the scientific, financial, and commercial framework for enabling rapid translation of innovative science into clinical development.

Using its extensive and proven experience in research and drug development, the team at ValiRx selects and incubates promising novel drug candidates and guides them through an optimised process of development, from pre-clinical studies to clinic and investor ready assets.

to clinic and investor-ready assets.

ValiRx connects diverse disciplines across scientific, technical, and commercial domains, with the aim of achieving a more streamlined, less costly, drug development process. The team works closely with carefully selected collaborators and leverages the combined expertise required for science to advance.

Lead candidates from ValiRx's portfolio are outlicensed or partnered with investors through ValiRx subsidiary companies for further clinical development and commercialisation.

ValiRx listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL.

For further information, visit: www.valirx.com

Cautionary statement

Certain statements made in this announcement are forward-looking statements. Such statements are based on current expectations and assumptions and are subject to a number of risks and uncertainties that could cause actual events or results to differ materially from any expected future events or results expressed or implied in these forward-looking statements. Persons receiving this announcement should not place undue reliance on forward-looking statements. Unless otherwise required by applicable law, regulation or accounting standard, the Company does not undertake to update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

ROMEADFLELSLEFA